Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)
Recruiting
N/A
Interventional Study
PARKINSON DISEASE (Disorder)
Multiple Sclerosis (MS) - Relapsing-remitting
Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 1 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 300 (estimated)
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Glucosinolates (GLs) are phytocompounds mainly found in the Cruciferae (Brassicacea) and Moringa oleifera plants. The hydrolysis of GLs by myrosinase led to the production of isothiocyanate (ITCs). ITCs consumption was associated with different health promoting effects, including to neuroprotective, anti-oxidant and anti-inflammatory capacities. In particular, they showed neuroprotective effects i…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Inclusion Criteria for PD:
* Male or female patients aged between 45-75 years old.
* Clinical diagnosis of PD according to UK Brain Bank Criteria.
* 3 months of clinical stability before study enrolment.
* Anti-parkinsonian medication is fixed for at least 3 months prior to stu…
Contacts